Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01) by 김혜련
RESEARCH ARTICLE Open Access
Treatment strategy and outcomes in locally
advanced head and neck squamous cell
carcinoma: a nationwide retrospective
cohort study (KCSG HN13–01)
Yun-Gyoo Lee1†, Eun Joo Kang2†, Bhumsuk Keam3* , Jin-Hyuk Choi4, Jin-Soo Kim5, Keon Uk Park6,
Kyoung Eun Lee7, Jung Hye Kwon8, Keun-Wook Lee9, Min Kyoung Kim10, Hee Kyung Ahn11, Seong Hoon Shin12,
Hye Ryun Kim13, Sung-Bae Kim14 and Hwan Jung Yun15*
Abstract
Background: By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell
carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians
in real-world practice.
Methods: This is a multi-institutional study enrolled the patients with stage III to IVB LA-HNSCC, except for
nasopharyngeal carcinoma, from 2004 to 2015 in thirteen referral hospitals capable of multidisciplinary care.
Results: A total of 445 LA-HNSCC patients were analyzed. The median age was 61 years (range, 24–89). The primary
tumor location was the oropharynx in 191 (43%), oral cavity in 106 (24%), hypopharynx in 64 (14%), larynx in 57
(13%) and other sites in 27 (6%). The most common stage was T2 in 172 (39%), and N2 in 245 (55%). Based on
treatment intents, 229 (52%) of the patients received definitive concurrent chemoradiotherapy (CCRT) and 187
(42%) underwent surgery. Approximately 158 (36%) of the study population received induction chemotherapy (IC).
Taken together, 385 (87%) of the patients underwent combined therapeutic modalities. The regimen for definitive
CCRT was weekly cisplatin in 58%, 3-weekly cisplatin in 28% and cetuximab in 3%. The preferred regimen for IC was
docetaxel with cisplatin in 49%, and docetaxel, cisplatin plus fluorouracil in 27%. With a median follow-up of 39
months, one-year and two-year survival rates were 89 and 80%, respectively. Overall survival was not significantly
different between CCRT and surgery group (p = 0.620).
Conclusions: In patients with LA-HNSCC, the majority of patients received combined therapeutic modalities.
Definitive CCRT, IC then definitive CCRT, and surgery followed by adjuvant CCRT or radiotherapy are the preferred
multidisciplinary strategies in real-world practice.
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Background
Head and neck squamous cell carcinoma (HNSCC) and
its associated variants originate from multiple anatomic
subsites in the oral cavity, oropharynx, hypopharynx and
larynx. Given the heterogeneous biology of HNSCC at
each subsite, treatments are complex. Generally, the
primary tumor location, stage of tumor and lymph node,
and pathologic characteristics guide specialized treatments
including surgical procedures, radiotherapy, and/or
systemic chemotherapy [1].
Around 40% of patients with HNSCC present with
limited or early-stage disease, in which treatment is or-
dinarily single modality, either surgery or radiotherapy
[2, 3]. The locally advanced (LA) HNSCC comprises the
remaining 60% of patients, whom multidisciplinary
modal therapy is generally recommended with either
surgery followed by postoperative radiotherapy or
chemoradiotherapy (CCRT), or definitive CCRT [1, 3].
Despite decades of research in the area of LA-HNSCC
treatment, the clinical significance of induction chemo-
therapy (IC) has not been conclusive [4]. Regarding
multimodal approaches for HNSCC treatment, thera-
peutic strategies in clinical practice depend on a multidis-
ciplinary team approach at each hospital [1, 5]. The most
effective treatment modality has yet to be established.
We describe the real-world patterns for the initial treat-
ment of LA-HNSCC in a large nationwide cohort treated
with multidisciplinary treatment modalities. By studying
this population, in which patients received multidisciplin-
ary treatment, we aim to provide valuable insights regard-
ing the optimal therapeutic strategy for physicians.
Methods
Patients
This study enrolled 445 patients who were pathologically
confirmed with LA-HNSCC between January 2005 and
December 2015 at 13 tertiary referral hospitals located
in the Republic of Korea. All the participating hospitals
have their own multidisciplinary team for head and neck
cancer with specialists.
LA-HNSCC was defined as clinical stage III to IVB
based on the 7th edition of the American Joint Commit-
tee on Cancer [6]. Adults patients aged 20 years or older
with primary squamous cell carcinoma of oropharynx,
hypopharynx, larynx, oral cavity, or nasal cavity were
included for analysis. Patients with biopsy-proven squa-
mous cell carcinoma at the cervical lymph node without
known origin were regarded to be of head and neck
origin and were also included in this study. HPV positivity
based on the results from either HPV DNA by real-time
PCR or p16 expression by immunohistochemistry,
depending on availability in each participating institution.
We excluded patients with nasopharyngeal cancer
which differs from other HNSCC in its epidemiology,
pathology, natural history and treatment, patients with
distant metastasis at initial diagnosis and patients with a
previous secondary malignancy diagnosed within 3 years
of HNSCC diagnosis. The Institutional Review Board for
main hospital (IRB-H-1304-089-481) and each partici-
pating hospital approved this study. Medical records
were retrospectively reviewed for patients who were
diagnosed with LA-HNSCC.
Multidisciplinary treatment
In principle, all patients were treated according to specific
treatment protocols established at each participating
hospital. The treatment modality, including surgery,
chemotherapy, and radiotherapy, was decided according
to a multidisciplinary team approach of each hospital.
When the opinions disagreed between each discipline, the
agreed recommendations of the multidisciplinary care
team were followed. IC is defined as chemotherapy which
facilitates subsequent local therapy such as definitive
CCRT or surgery. Inadequate treatment group was de-
fined as patients who did not receive subsequent definitive
treatment after diagnosis because of patient’s refusal or in-
tolerance. All imaging studies, including MRI or CT of the
head and neck, were assessed, as well as chest CT, abdom-
inal CT, brain MRI, or positron emission tomography/CT
scans where available, obtained when there were specific
symptoms or clinical suspicion. Follow-up imaging was
performed based on the protocol of each hospital.
Study outcomes
The primary outcome was to identify treatment patterns
that are being performed in real-world practice for the
treatment of LA-HNSCC. The secondary outcome was
to compare progression-free survival (PFS) and overall
survival (OS) by treatment strategy and/or primary site.
PFS was defined as time from diagnostic date of HNSCC
until disease recurrence, progression by RECIST criteria
or death of any cause. OS was defined as time from date
of diagnosis to death, regardless of cause.
Statistical analysis
Chi-square tests and independent t-tests were used to
compare categorical and continuous variables between
groups, as appropriate. Multivariate Cox regression ana-
lysis was used for PFS and OS. Statistical significance
was set at a two-sided P-value < 0.05. All statistical ana-
lyses were performed using Stata 16.0 software (Stata
Corp LP, College Station, TX, USA).
Results
Patient characteristics
A total of 445 patients with LA-HNSCC were enrolled
in this study and analyzed retrospectively. The median
age was 61 years (range, 24–89), and 385 (87%) were
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male. The primary tumor location was the oropharynx
in 191 (43%) of the cases, followed by oral cavity in 106
(24%), hypopharynx in 64 (14%), larynx in 57 (13%), and
other sites in 27 (6%). Other sites included maxillary
sinus, nasal cavity, ethmoid sinus, and unknown primary
squamous carcinoma. The most common clinical tumor
(T) and lymph node (N) stage was T2 in 172 (39%) and
N2 in 245 (55%), respectively. About 58% (256) of study
patients was unknown for HPV infection. Of 189 pa-
tients who were tested for HPV status, 48% (90/189)
were positive. Table 1 summarized the demographics of
study population.
Treatment strategy
Based on treatment intents, patients received definitive
CCRT in 229 (52%) of cases and surgery in 187 (42%).
The remaining 29 (7%) did not receive adequate treat-
ment. Approximately 158 (36%) of the study population
received IC. In 229 patients from the CCRT group, 45%
(103 patients) underwent IC prior to definitive CCRT. In
187 patients from the surgery group, 17% (32 patients)
received IC followed by surgery with curative intent. Of
the 29 patients in the inadequate treatment group, about
80% (23/29) failed to receive subsequent treatment after
IC. Taken together, 385 (87%) of the patients were
treated with combined treatment modalities (Fig. 1).
Treatment characteristics
Details of the treatment modalities are shown in Table 2.
For 158 patients receiving IC, the preferred regimen was
DP (docetaxel and cisplatin) in 49% (77/158) of the
patients, TPF (docetaxel, cisplatin and fluorouracil) in
27% (42/158), FP (Fluorouracil and cisplatin) in 18%
(28/158), and other therapies in 7% (11/158). The
median number of cycles for chemotherapy was 3 (range
1–5). The best overall response was a complete response
(CR) in 16% (25/158), a partial response (PR) in 55%
(87/158), stable disease (SD) in 20% (31/158) and
progressive disease (PD) in 10% (15/158) of the patients.
Patients presenting a good performance status were
more likely to receive IC compared with those with a
poor performance status (p < 0.001). For oropharyngeal
and hypopharyngeal cancer, patients received IC more
frequently compared with those in the oral cavity and
larynx group (p < 0.001). For clinical T and N classifica-
tion, patients presenting advanced stage T and N were
more likely to receive IC (p < 0.001, Supplementary
Table 1).
Of the 305 patients receiving CCRT, the goal was to
treat 75% (229/305) with definitive and 24% (76/305)
with adjuvant therapy. The preferred regimen for defini-
tive CCRT was weekly cisplatin for 58%, 3-weekly cis-
platin for 28%, and 5-fluorouracil and cisplatin for 10%
of the patients. Cetuximab was selected for only 3% of
the patients. The median dose of irradiation was 67.5Gy
(range 32–72). The best overall response was a CR in
65%, PR in 19%, SD in 9%, and PD in 7%. The CCRT
regimen was not different between the definitive and
adjuvant setting (p = 0.151, unpublished data).
Study outcomes
With a median follow-up period of 39.3 months (95% CI
35.4–43.1), 113 deaths were observed. For 445 patients,
1-year and 2-year survival rates were 88.7% (95% CI
85.2–91.3) and 79.8% (95% CI 75.4–83.4), respectively. A
median OS was not reached. When drawing a flowchart
with respect to treatment intent, 52% (229/445) of the
patients received definitive CCRT, and 42% (187/445)
underwent surgery. The most frequently adopted treat-
ment strategy was definitive CCRT in 28% (126/445), IC
followed by definitive CCRT in 23% (103/445), and
surgery followed by adjuvant CCRT or radiotherapy in
14% (63/445) (Fig. 1).
When comparing survival probabilities between the
CCRT and surgery groups, OS was not significantly dif-
ferent (HR 0.90; 95% CI 0.61–1.35; p = 0.620) (Fig. 2a).
When patients failed to receive adequate treatment fol-
lowing IC or refused anticancer treatment, OS was the
poorest (Fig. 2a). To evaluate the clinical role of IC, we
analyzed the prognostic impact of IC in the CCRT and
surgery groups. In the CCRT group, survival probabil-
ities were not significantly different by administration of
IC (HR 0.99; 95% 0.57–1.73; p = 0.973) (Fig. 2b). In the
surgery group, however, patients receiving IC prior to sur-
gery exhibited inferior OS (HR, 1.96; 95% CI, 1.00–3.86;
p = 0.05) (Fig. 2c). After adjustment of covariate, the
estimates of IC in surgery group was not statistically
significant (HR 1.48; 95% CI 0.58–3.82; p = 0.423).
According to the primary tumor location, patients with
oropharyngeal cancer showed better survival probability
than non-oropharyngeal cancer (HR 0.65; 95% CI 0.44–
0.96, p = 0.029) (Fig. 2d, e). Compared with other primary
tumor locations, oral cavity cancer showed the worst sur-
vival outcome (Fig. 2D). In oral cavity cancer, the surgical
approach exhibited better survival probability than CCRT
(HR 0.43; 95% CI 0.21–0.86; p = 0.017) (Fig. 2f).
Multivariate analyses for PFS and OS
Multivariate analyses for PFS revealed that primary
tumor location of other sites (maxillary sinus, nasal
cavity, ethmoid sinus, and unknown primary squamous
carcinoma versus oropharyngeal cancer), advanced T
classification (from one unit to the next), and inadequate
treatment (vs. CCRT) were significant predictors for PFS
(Table 3, Supplementary Table 2).
With respect to mortality, HPV positivity (vs. negative)
was an independent prognostic indicator for improved
survival. Primary tumor location in the oral cavity (vs.
Lee et al. BMC Cancer          (2020) 20:813 Page 3 of 9
Table 1 Baseline characteristics of locally advanced head & neck squamous cell carcinoma
Characteristics Treatment Strategy p-value*
CCRT group n = 229
(51.5%)
Surgery group n = 187
(42.0%)
Inadequate Tx n = 29
(6.5%)
Total N = 445
(100%)
Age, median [range], years 61 [30–81] 60 [24–89] 0.633 67 [36–82] 61 [24–89]
Gender 0.125
Female 25 (41.7%) 30 (50.0%) 5 (8.3%) 60 (100%)
Male 204 (53.0%) 157 (40.8%) 24 (6.2%) 385 (100%)
ECOG PS < 0.001
0 40 (72.7%) 9 (16.4%) 6 (10.9%) 55 (100%)
1 153 (71.2%) 47 (21.9%) 15 (7.0%) 215 (100%)
2 12 (70.6%) 3 (17.7%) 2 (11.8%) 17 (100%)
3 4 (100%) 0 (0.0%) 0 (0.0%) 4 (100%)
Unknown 20 (13.0%) 128 (83.1%) 6 (3.9%) 154 (100%)
Smoking history < 0.001
Never 37 (37.4%) 54 (54.6%) 8 (8.1%) 99 (100%)
Former 62 (46.3%) 62 (46.3%) 10 (7.5%) 134 (100%)
Current 53 (49.5%) 46 (43.0%) 8 (7.5%) 107 (100%)
Unknown 77 (73.3%) 25 (23.8%) 3 (2.9%) 105 (100%)
Alcohol history < 0.001
Do not drink 49 (40.8%) 60 (50.0%) 11 (9.2%) 120 (100%)
Drink alcohol 71 (43.6%) 83 (50.9%) 9 (5.5%) 163 (100%)
Unknown 109 (67.3%) 44 (27.2%) 9 (5.6%) 162 (100%)
Primary tumor location < 0.001
Oropharynx 105 (55.0%) 73 (38.2%) 13 (6.8%) 191 (100%)
Oral cavity 30 (28.3%) 70 (66.0%) 6 (5.7%) 106 (100%)
Hypopharynx 42 (65.5%) 16 (25.0%) 6 (9.4%) 64 (100%)
Larynx 31 (54.4%) 24 (42.1%) 2 (3.5%) 57 (100%)
Others 21 (77.8%) 4 (14.8%) 2 (7.4%) 27 (100%)
Histologic grade < 0.001
Well differentiated 22 (32.4%) 41 (60.3%) 5 (7.4%) 68 (100%)
Moderate differentiated 58 (36.5%) 97 (61.0%) 4 (2.5%) 159 (100%)
Poorly differentiated 42 (63.6%) 21 (31.8%) 3 (4.6%) 66 (100%)
Not assessed 107 (70.4%) 28 (18.8%) 17 (11.4%) 152 (100%)
T classification < 0.001
T1 21 (31.8%) 43 (65.2%) 2 (3.0%) 66 (100%)
T2 85 (49.4%) 80 (46.5%) 7 (4.1%) 172 (100%)
T3 57 (60.6%) 30 (31.9%) 7 (7.5%) 94 (100%)
T4a / T4b 51 / 14 (58.6%) 31 / 2 (29.7%) 11 / 2 (11.7%) 93 / 18 (100%)
Unknown 1 (50.0%) 1 (50.0%) 0 (0.0%) 2 (100%)
N classification < 0.001
N0 25 (48.1%) 24 (46.2%) 3 (5.8%) 52 (100%)
N1 56 (40.0%) 79 (56.4%) 5 (3.6%) 140 (100%)
N2 142 (58.0%) 83 (33.9%) 20 (8.2%) 245 (100%)
N3 6 (85.7%) 1 (14.3%) 0 (0.0%) 7 (100%)
Unknown 0 (0.0%) 0 (0.0%) 1 (100%) 1 (100%)
P16/HPV status < 0.001
Negative 16 (16.2%) 79 (79.8%) 4 (4.0%) 99 (100%)
Positive 45 (50.0%) 43 (47.8%) 2 (2.2%) 90 (100%)
Unknown 168 (65.6%) 65 (25.4%) 23 (9.0%) 256 (100%)
p-value was calculated by t-test or Chi-square test as appropriate between CCRT and surgery group
PS Performance status, HPV Human papillomavirus
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oropharynx), advanced T and N classification, and inad-
equate treatment (vs. CCRT) were independent predic-
tors for poor survival (Table 3, Supplementary Table 3).
Discussion
This nationwide retrospective cohort study including
445 patients with LA-HNSCC found that 87% of the
patients received multimodality treatment modalities.
Based on treatment intents, 52% of the patients received
definitive CCRT, while 42% underwent surgery.
Approximately 36% of the study population received IC.
Regarding multidisciplinary approaches, the preferred
treatment strategy was definitive CCRT in 28%, IC then
definitive CCRT in 23%, surgery followed by adjuvant
CCRT in 14% or adjuvant radiotherapy in 14% of the pa-
tients. Overall outcomes for one- and two-year survival
rates were 88.7 and 79.8%, respectively.
In the context of LA-HNSCC therapeutics, our study
provides valuable information for drawing a general
treatment landscape. OS was not different between
definitive the CCRT and surgery groups. Given that IC
was administered in approximately one-third of our
patients with more advanced disease, IC did not show
survival advantages in either the CCRT or surgery group.
Though a recommendation for IC, except for the pur-
pose of laryngeal preservation, has yet to be established,
[7–9] only 19% of our patients with laryngeal cancer
received IC. In other words, the real-world practice
indicated that IC was being performed more actively for
Fig. 1 Flowchart for the treatment of locally advanced head & neck squamous cell carcinoma (N = 445). CCRT, concurrent chemoradiotherapy;
CTx, chemotherapy; RT, radiotherapy; Tx, treatment






Regimen Docetaxel + Cisplatin 77 (48.7%)
Docetaxel + Cisplatin +
Fluorouracil
42 (26.6%)
Fluorouracil + Cisplatin 28 (17.7%)
Others 11 (7.0%)
Number of cycles Median: 3 cycles Range 1–5
Best overall response Complete response 25 (15.8%)
Partial response 87 (55.1%)
Stable disease 31 (19.6%)





CCRT regimen Weekly cisplatin 133 (58.1%)
3-weekly cisplatin 63 (27.5%)









Complete response 148 (65.2%)
Partial response 42 (18.5%)
Stable disease 21 (9.3%)
Progressive disease 16 (7.1%)
Lee et al. BMC Cancer          (2020) 20:813 Page 5 of 9
advanced stages of LA-HNSCC other than laryngeal can-
cer without definite evidence of its survival advantages.
The patients receiving IC prior to surgery showed
poorer OS than the patients receiving surgery without
IC. The reason is that IC was performed when the
tumor is bulky, and node is advanced (Supplementary
Table 1). Approximately 23 patients (5%) recognized in
Fig. 1 did not receive subsequent definitive treatment
after IC and showed the worst OS (Fig. 2a). Residual
toxicity following IC could complicate succeeding defini-
tive treatments, especially surgery, so physicians need to
be more cautious in selecting the sequence of treatment
modalities. In oral cavity cancer, which had the worst
survival outcome, the surgical approach showed survival
benefits over CCRT in our study. These results provide
us valuable insights to build the optimal treatment
strategy in oral cavity cancer.
Based on the TAX-323/EORTC-24971 and TAX-324
phase III trials, the TPF regimen as IC is now accepted
to be an evidence-based regimen of choice [10–12]. This
is because the TPF regimen proved clear survival bene-
fits over FP chemotherapy in unresectable LA-HNSCC
[13]. Regarding toxicities, almost 80% of the patients
treated with TPF regimen experience grade 3–4 neutro-
penia and 12% developed infection. Poor compliance
(about 75% of patients completed the protocol) due to
toxicities was another concern for the TPF regimen. In
our study, DP was the most frequently administered
regimen. For toxicity and adherence concerns, DP may
be considered the preferred regimen in Korea instead of
TPF [14, 15]. Given that there is currently no direct
study comparing outcomes the DP and the TPF regi-
mens, further research regarding optimal IC regimens is
needed.
CCRT with cisplatin remains the gold standard for the
treatment of LA-HNSCC [16]. In our LA-HNSCC popu-
lation, definitive CCRT was the main therapeutic modal-
ity for more than half (52%) of the patients. Regarding
the schedule of cisplatin during definitive CCRT, weekly
cisplatin was used approximately two times more
frequently than 3-weekly schedule (58% vs. 28%). In a re-
cent meta-analysis, Szturz et al. found that both high-
and low-dose cisplatin regimens yield similar survival
outcomes for postoperative and definitive CCRT [17].
This finding is consistent with a population based study
of US military veterans that included over 2900 patients
Fig. 2 a Overall survival by Treatment intent (N = 445). b Overall
survival by induction chemotherapy in CCRT group. c Overall survival
by induction chemotherapy in Surgery group. d Overall survival
according to location of the primary site. e Overall survival between
oropharyngeal and non-oropharyngeal cancer. f Overall survival of
oral cavity cancer by treatment intent
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[18]. Given that 3-weekly cisplatin was associated with
significantly more toxicity than weekly -cisplatin, tolerability
is a key factor in selection. Preference for weekly cisplatin
in our study reflects the physicians’ tendency to value safety
[19, 20]. For postoperative CCRT in high-risk disease, a
recent phase III study, conducted at a single institution in
India, demonstrated that two-year locoregional control was
superior in patients receiving 100mg/m2 cisplatin every 3
weeks compared with 30mg/m2 cisplatin weekly (73.1% vs.
58.5%, p = 0.014) [6]. Because 3-weekly cisplatin results in
more toxicity than weekly cisplatin, physicians need to
choose a treatment regimen that balances efficacy with
toxicity.
Our multivariate analyses demonstrated that positive
HPV status was a good independent prognostic factor,
consistent with other studies [21–23]. However, these
results should be interpreted carefully, because the status
of HPV infection was tested for only 43% of the patients
and the prognostic role of HPV status in non-
oropharyngeal cancer is inconclusive [24]. In particular,
oral cavity cancer conferred the worst survival. There-
fore, special attention to improve outcome in oral cavity
cancer is warranted.
Several limitations to our study need to be addressed.
First, data for this outcome study was collected and ana-
lyzed retrospectively, which has inherent selection bias.
However, a relatively large number of LA-HNSCC pa-
tients (n = 445) were evaluated from thirteen nationwide
referral hospitals, which represented a real-world
situation in Korea. It will certainly be considered that
the number of patients in our study is not sufficient to
draw a definitive conclusion. Second, heterogeneous
patients with tumor arising from various sites received
different therapeutics. This limits the accurate interpret-
ation of the study results. Lastly, our study could not
collect toxicity profiles due to the risk of underestimat-
ing the retrospectively collected data.
Conclusions
Most patients with LA-HNSCC were treated with com-
bined multidisciplinary therapeutics and showed favorable
survival outcomes. Definitive CCRT, IC then definitive
CCRT, and surgery followed by adjuvant CCRT or radio-
therapy are the preferred multidisciplinary strategies.
Though one-third of the patients received IC, its clinical
role should be further evaluated in clinical trials. Our re-
sults are essential to understanding the patterns of multi-
disciplinary team approaches in real-world practice and to
provide valuable insights regarding optimal therapeutic
strategies for physicians. Prospective data is still needed to
better assess therapy modalities in LA-HNSCC.
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